What nature never thought to make.
Most proteins
are undruggable.
Established technologies only address a fraction of the drug targets that could make an impact on human health. 70% of drug targets are too complex for small molecules and beyond the reach of biologics, others only yield to injectable therapeutics.
Until now.
01
Macrocycles
Nature’s solution
to hard targets.
Small Molecules can permeate cells and be orally delivered but struggle to bind complex targets. Biologics can only act on targets displayed outside of cells and are typically injected.
Nature’s macrocycles evolved to transcend the boundaries of cell permeability and oral bioavailability to engage complex targets with high specificity. By harnessing these insights from nature, synthetic macrocycles bridge the gap between small molecules and biologics.
Big Biologics
Medium
Macrocycles
Small
Molecules
02
Macrocycle Discovery Platform
From serendipity
to design.
Our AI-enhanced discovery platform engineers synthetic macrocycles that mimic nature’s macrocycles. A new modality requires a new approach: we’ve built technologies to intelligently design, rapidly synthesize, and screen cyclic peptide macrocycles.
03
About
Unnatural Products for uncommon outcomes.
We’re a California-based biotech company using our platform to tackle the hard targets that will change the future of medicine.
Founded by macrocycle pioneers whose academic work uncovered how Nature’s macrocycles work, UNP is a team of passionate scientists, engineers, and experienced drug developers.
07
Our Partners
08
Our Investors
